Search Results for "Graves Disease And Agent Orange "

23:21 EDT 28th March 2017 | BioPortfolio

Matching Channels

Graves' disease

Congenital Graves' disease

Eye disease

Xofigo (radium-223 dichloride)

New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases. Xofigo shown in a pivotal phase III trial to significantly improve overall survival. Xofigo® with...

p38 mitogen activated protein kinase MAPK Inhibitors

The next generation of p38 mitogen-activated protein kinase (MAPK) inhibitors has reached clinical proof-of-concept studies in phase II in a broad range of indications. While the previous generation o...

Matching News

Research Linking Agent Orange, Hypertension May Finally Pressure VA To Act

There has been an ongoing battle between veterans and the VA over insurance coverage related to diseases veterans say are caused by their exposure to Agent Orange in Vietnam. The VA has been reluctant...

Antithyroid Drugs Correct Neutropenia in Graves' Disease

Find out how antithyroid medications impact neutrophil counts in patients with Graves disease. Clinical Endocrinology

Vietnam war veteran develops rare cancer after exposure to Agent Orange

A veteran with a rare type of cancer may have developed the condition after being exposed to Agent Orange during the Vietnam War, reveal doctors writing in the journal BMJ Case Reports.

Graves' Disease in Children: Long-term Outcomes of Therapy

How do children who received treatment for Graves disease fare over the long term? Clinical Endocrinology

Apitope enrols first patient in Phase I trial of ATX-GD-59 to treat Graves’ disease

Drug discovery and development company Apitope has enrolled the first patient in the Phase I clinical trial of its peptide therapy, ATX-GD-59, to treat Graves’ disease.

The One Controversial Scientist Behind VA’s Refusal To Cover Agent Orange-Related Sickness

Alvin Young's nickname is Dr. Orange and he thinks veterans who complain about sickness that they think is related to a toxic herbicide used in the Vietnam War are simply “freeloaders,” making up ...

Findings Indicate Promise for Treatment of Graves Disease and Ocular Disorders

NewsA new class of therapies may be on the horizon for thyroid eye disease (TED) and other destructive scarring conditions.

STAT6 deficiency ameliorates Graves’ disease severity by suppressing thyroid epithelial cell hyperplasia

Matching PubMed Articles

Simultaneous induction of Graves' hyperthyroidism and Graves' ophthalmopathy by TSHR genetic immunization in BALB/c mice.

Graves' disease is the most common form of autoimmune thyroid disorder, characterized by hyperthyroidism due to circulating autoantibodies. To address the pathological features and establish a therape...

CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.

Graves' disease, an autoimmune disease with heterogeneous symptoms including Graves' orbitopathy, has a combined genetic/environmental background, where variations within CD28/CTLA-4/ICOS genes are co...

Limited cutaneous systemic sclerosis arising in a patient with Graves' disease.

Although Graves' disease and systemic sclerosis are both autoimmune disorders, their relationship is rarely reported. We present the case of a Filipino woman with goitre and thyrotoxic signs and sympt...

Diagnostic Accuracy of Fine Needle Aspiration in Thyroid Nodules Arising in Patients with Graves Disease.

Cytopathologic interpretation in Graves disease (GD) is considered challenging due to significant cellular atypia.

Mortality in Graves' orbitopathy is increased and influenced by gender, age and pre-existing morbidity. A nationwide Danish register study.

It is unclear whether the excess mortality associated with Graves' disease differs between individuals with Graves' orbitopathy (GO) and without (GD).

Search Whole site using Google

Quick Search
Advertisement Advertisement